Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €55.04 EUR
Change Today +0.184 / 0.34%
Volume 979.0
As of 11:22 AM 08/4/15 All times are local (Market data is delayed by at least 15 minutes).

novo-nordisk a/s-spons adr (NOVA) Snapshot

Open
€54.43
Previous Close
€54.86
Day High
€55.31
Day Low
€54.29
52 Week High
08/4/15 - €55.31
52 Week Low
08/8/14 - €31.98
Market Cap
143.1B
Average Volume 10 Days
1.2K
EPS TTM
--
Shares Outstanding
2.1B
EX-Date
03/19/15
P/E TM
--
Dividend
€0.75
Dividend Yield
1.25%
Current Stock Chart for NOVO-NORDISK A/S-SPONS ADR (NOVA)

Related News

No related news articles were found.

novo-nordisk a/s-spons adr (NOVA) Details

Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Biopharmaceuticals. The Diabetes Care segment covers insulins, GLP-1 analog, obesity, and oral antidiabetic drugs, as well as other protein related products comprising glucagon, protein related delivery systems, and needles. The Biopharmaceuticals segment offers products in the areas of haemophilia care, growth hormone therapy, and hormone replacement therapy. The company markets and distributes its products through its subsidiaries, distributors, and independent agents. Novo Nordisk A/S was founded in 1925 and is headquartered in Bagsvaerd, Denmark.

39,062 Employees
Last Reported Date: 04/30/15
Founded in 1925

novo-nordisk a/s-spons adr (NOVA) Top Compensated Officers

Chief Executive Officer, President and Member...
Total Annual Compensation: kr15.2M
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: kr8.1M
Chief Science Officer, Executive Vice Preside...
Total Annual Compensation: kr8.1M
Chief of Staff, Executive Vice President and ...
Total Annual Compensation: kr5.5M
Executive Vice President of China, Pacific & ...
Total Annual Compensation: kr5.5M
Compensation as of Fiscal Year 2013.

novo-nordisk a/s-spons adr (NOVA) Key Developments

Novo Nordisk Receives FDA Approval for Flexpro® Penmate® for People with Growth Hormone-Related Disorders

Novo Nordisk announced the U.S. Food and Drug Administration (FDA) approval of FlexPro® PenMate®, designed for users of Norditropin® FlexPro® 5 mg, 10 mg, and 15 mg pens who dislike needles and prefer them to be hidden during the injection process. FlexPro® PenMate® has been developed exclusively for use with the Norditropin® FlexPro® 5, 10, and 15 mg pens. It is a cylindrical attachment that is designed to conceal the needle so patients cannot see it being inserted into their skin during injection.  The Norditropin® FlexPro® pen slides into FlexPro® PenMate® and twists into a locked position.  The needle is then attached, and the injection process can begin.  FlexPro® PenMate® features a large gripping surface so patients can firmly hold the pen during injection. Norditropin® FlexPro® is the only prefilled growth hormone injection pen that can be stored outside of the refrigerator for up to 21 days after first use. All Norditropin® products must be refrigerated prior to first use.  Do not freeze. After initial use, Norditropin® pens can either be stored outside of the refrigerator (up to 77 degrees F [25 degrees C]) for use within 3 weeks, or in the refrigerator (between 36 degrees F and 46 degrees F [2 degrees C and 8 degrees C]) for use within 4 weeks. Norditropin® is a prescription medicine that contains human growth hormone and is used to treat children who are not growing because of low or no growth hormone.; children who are short (in stature) and who have Noonan syndrome or Turner syndrome.; children who are short (in stature) because they were born small (small for gestational age-SGA) and have not caught-up in growth by age 2 to 4 years.; the adults who did not make enough growth hormone when they were children or when they became adults.

Zosano Pharma Announces Discontinuation of Novo Nordisk GLP-1 Patch Collaboration

Zosano Pharma Corporation announced that Novo Nordisk has notified Zosano of its intention to discontinue the collaboration agreement related to development of a transdermal presentation of select NVO glucagon-like peptide-1 (GLP-1) analogues. Zosano has been notified that the decision relates to a strategic prioritization of NVO's research portfolio despite continued progress during the collaboration period. Upon the expected termination of the agreement, all technology rights licensed to Novo Nordisk related to the field of GLP-1 products will revert to Zosano. Zosano and NVO entered into a collaboration agreement in January 2014 to develop a new transdermal presentation of NVO proprietary human GLP-1 analogues, to be administered once weekly using Zosano's microneedle patch system for the treatment of type 2 diabetes.

Novo Nordisk to Stop Selling Insulin Drug Tresiba in Germany

Novo Nordisk announced that it has decided to stop selling Tresiba, the company's novel long-acting insulin drug, in Germany owing to a disagreement on the medicine's pricing. Novo took the decision after it could not agree on Tresiba's pricing in negotiations with GKV-Spitzenverband, an association of healthcare companies in Germany. At present, nearly 40,000 diabetic patients across Germany use the insulin drug and Novo will not stop the product's supply till the end of September 2015 so as to enable such patients to switch over to another safe insulin alternative. The European Medicines Agency has recognized Tresiba as providing significant benefits, but GKV-Spitzenverband had decided to fix the drug's price at the level of regular human insulin.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NOVA:GR €55.04 EUR +0.184

NOVA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $69.95 USD +0.22
Allergan plc $331.00 USD -3.92
Amgen Inc $174.80 USD -0.79
Bristol-Myers Squibb Co $64.84 USD -0.50
Eli Lilly & Co $84.05 USD -0.09
View Industry Companies
 

Industry Analysis

NOVA

Industry Average

Valuation NOVA Industry Range
Price/Earnings 36.6x
Price/Sales 11.6x
Price/Book 33.8x
Price/Cash Flow 28.9x
TEV/Sales 9.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVO-NORDISK A/S-SPONS ADR, please visit www.novonordisk.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.